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ROLE OF POSITRON EMISSION TOMOGRAPHY (PET) IN
ADVANCED STAGE NON-SMALL CELL LUNG CANCER PATIENTS
TREATED WITH CISPLATIN-BASED DOUBLETS
V. Gebbia, U. Ficola, G. Mancuso, Arcara C. La Maddalena. Clinic
Department of Experimental Oncology and Clinical Applications,
University of Palermo, Italy
PET is an important cancer imaging tool, both for diagnosis
and staging, as well as offering prognostic information based on
response. PET scan with the glucose analogue FDG is based on
the enhanced glucose metabolism of lung cancer cells. FDG
undergoes the same uptake as glucose but is metabolically
trapped and accumulated in the cancer cell after phosphorylation
by hexokinase. In our unit PET scan is used to rule out distant dis-
ease in staging patients before starting loco-regional treatments
or CT. Patients classified as stage IV were treated with 3 cycles
of cisplatin-based regimen (80 mg/m2 q21d) in combination with
gemcitabine (1000 mg/m2 d1 + 8) or vinorelbine (25 mg/m2
d1 + 8) every 3 weeks. Patients were restagedwith CT scan accord-
ing to the Recist criteria and with PET. To date 61 patients with
stage IV NSCLC have been included in this analysis with a median
age of 64 years and a median ECOG PS of 1 (r.0–1), without uncon-
trolled diabetes. All patients had measurable disease and fulfilled
all the criteria necessary to receive cisplatinum-based CT. Up to
date objective response rate according to CT-guided dimensional
criteria has been 36% with no CR, while SD was recorded in 34% of
cases and PD in 30%. PET after 3 cycles has shown good correla-
tion with objective response (p = 0.046), but PET scan also showed
metabolic response in patients with CT-documented SD in 6
cases. The correlation of metabolic response to survival parame-
ters, i.e. TTP and overall survival, is still ongoing. This preliminary
data are in accord to data reported by other authors on the effi-
cacy of PET scan in evaluating the clinical efficacy of any CT reg-
imen even if at present it should not substitute classical imaging
in restaging advance NSCLC. Further studies are needed to clarify
the role of PET scan in early prediction of clinical efficacy of CT.
doi:10.1016/j.ejcsup.2008.06.093
MALIGNANT PLEURAL MESOTHELIOMA: SCHEME THERAPEUTIC
AFTER STANDARD TREATMENT (STUDY OF PHASE II)
S. Vitello a, G. Giarratano a, ssa Oriana Maiorana a, Di
Cristina b. aU.O.Oncologia Medica Osp.S.Elia,Caltanissetta,
Italy. bU.O. Oncologia Castelvetrano (TP), Italy
On the basis of improvement survival in a randomised
trial, the combination of pemetrexed and cisplatin has
received indication for the treatment of unresectable meso-
thelioma.
In patients on progression after the standard chemotherapeu-
tic there is not advised systemic treatment therapeutic. Neverthe-
less there are some patients that can be continue therapy
again.
For these patients in our structure we have adopted an regi-
men of phase II that includes:
Bleomicin 15 mg/m2 e.v. days 1,2
Oxaliplatin 85 mg/m2 e.v. day 1
Gemcitabine 1000 mg/m2 e.v. days 2,9
Repeated every 21–28 d.
In our structure we treated from April 2006 to December 2007 9
patients: 7 men/2 women, median 64 years, range 44-68; of the
patients 4 with stage II Butchart, 2 with stage III ,2 with
stage IV.
After 4 cycles the results are: 2 R.O.,2 S.D. After 8 cycles the
results were:
1 R.O. 3 SD.
The results and the moderate toxicity found (fever,mal-
aise,neurotoxicity and neutropenia grades I and II WHO) were
very encouraging.
doi:10.1016/j.ejcsup.2008.06.094
doi:10.1016/S1359-6349(08)00158-4
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